Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Change in Accured Expenses (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Change in Accured Expenses for 6 consecutive years, with -$5.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 161.89% to -$5.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$30.2 million, a 304.19% decrease, with the full-year FY2025 number at -$30.2 million, down 304.19% from a year prior.
  • Change in Accured Expenses was -$5.6 million for Q4 2025 at Lexicon Pharmaceuticals, up from -$14.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $11.1 million in Q2 2025 to a low of -$21.7 million in Q1 2025.
  • A 3-year average of -$747250.0 and a median of $1.6 million in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 443.93% in 2024, then plummeted 257.86% in 2025.
  • Lexicon Pharmaceuticals' Change in Accured Expenses stood at -$2.7 million in 2023, then surged by 443.93% to $9.1 million in 2024, then crashed by 161.89% to -$5.6 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Change in Accured Expenses are -$5.6 million (Q4 2025), -$14.0 million (Q3 2025), and $11.1 million (Q2 2025).